Skip to main content
SpringerLink
Log in

Valuation of biomarkers

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 12, 289–294 (2007).

    Article  CAS  Google Scholar 

  2. Hurko, O. The uses of biomarkers in drug development. Ann. NY Acad. Sci. 180, 1–10 (2009).

    Article  Google Scholar 

  3. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).

    Article  CAS  Google Scholar 

  4. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

    Article  Google Scholar 

  5. Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Int. Med. 125, 605–613 (1996).

    Article  CAS  Google Scholar 

  6. Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431–440 (1989).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orest Hurko is at Biologics Consulting Group, 400 North Washington Street, Suite 100, Alexandria, Virginia 22314-2353, USA.,

    Orest Hurko

  2. Graham K. Jones is at Pfizer, Groton, Connecticut, USA.,

    Graham K. Jones

Authors
  1. Orest Hurko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graham K. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orest Hurko.

Ethics declarations

Competing interests

Orest Hurko is a full-time employee of the Biologics Consulting Group, 400 North Washington Street, Alexandria, Virginia 22314–2353, USA. Biologics Consulting Group is an international consultancy that provides support with regulatory submissions to the US Food and Drug Administration. Graham K. Jones is a full-time employee at Pfizer.

Supplementary information

Supplementary information Box S1

Details of model and analysis (PDF 333 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hurko, O., Jones, G. Valuation of biomarkers. Nat Rev Drug Discov 10, 253–254 (2011). https://doi.org/10.1038/nrd3417

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3417

  • Springer Nature Limited

This article is cited by

Search

Navigation